Tax
Current Income Tax Expense
Vertex Pharmaceuticals Current Income Tax Expense remained flat by 0.0% to $300.20M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $283.23M to $300.20M. Over 2 years (FY 2023 to FY 2025), Current Income Tax Expense shows relatively stable performance with a -3.8% CAGR.
Analysis
StatementIncome Statement
SectionTax
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
ms_current_income_tax_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.30B | $1.13B | $1.20B |
| YoY Change | — | -12.6% | +6.0% |
Range$1.13B – $1.30B
CAGR-3.8%
Avg YoY Growth-3.3%
Median YoY Growth-3.3%
Current Income Tax Expense at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's current income tax expense?
- Vertex Pharmaceuticals (VRTX) reported current income tax expense of $300.20M in Q4 2025.
- How has Vertex Pharmaceuticals's current income tax expense changed year-over-year?
- Vertex Pharmaceuticals's current income tax expense increased by 6.0% year-over-year, from $283.23M to $300.20M.
- What is the long-term trend for Vertex Pharmaceuticals's current income tax expense?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's current income tax expense has grown at a -3.8% compound annual growth rate (CAGR), from $1.30B to $1.20B.